TrialThe Lancet. Infectious diseases2021

Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial.

Kimberly Davis et al.PubMed ↗Publisher ↗

No numbers read from the abstract.